This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Kelbæk, H. Articles by Thuesen, L. Search for Related Content PubMed PubMed Citation Articles by Kelbæk, H. Articles by Thuesen, L. Related Collections Related Articles

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions

3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) Trial

Henning Kelbæk, MD^_*,_*, Lene Kløvgaard, RN^_*, Steffen Helqvist, MD^_*, Jens F. Lassen, MD, Lars R. Krusell, MD, Thomas Engstrøm, MD^_*, Hans E. Bøtker, MD, Erik Jørgensen, MD^_*, Kari Saunamäki, MD^_*, Samir Aljabbari, MD^_*, Per Thayssen, MD, Anders Galløe, MD, Gunnar V.H. Jensen, MD^¶ and Leif Thuesen, MD

^_* Rigshospitalet, Copenhagen, Denmark
Skejby Sygehus, Skejby, Denmark
Odense Universitetshospital, Odense, Denmark
Gentofte Hospital, Gentofte, Denmark
^¶ Roskilde Hospital, Roskilde, Denmark.

Manuscript received November 8, 2007; revised manuscript received January 4, 2008, accepted January 7, 2008.

^_* Reprint requests and correspondence: Dr. Henning Kelbæk, Cardiac Catheterization Laboratory, Rigshospitalet, DK–2100 Copenhagen Ø, Denmark. (Email: henning.kelbaek{at}rh.regionh.dk).

Objectives: Our purpose was to evaluate the long-term use of sirolimus-eluting stents (SES) and bare-metal stents (BMS) in patients with complex coronary artery lesions.

Background: Although the use of SES has proved to be effective in patients with simple coronary artery lesions, there are limited data of the long-term outcome of patients with complex coronary artery lesions.

Methods: We randomly assigned 322 patients with total coronary occlusions or lesions located in bifurcations, ostial, or angulated segments of the coronary arteries to have SES or BMS implanted.

Results: At 3 years, major adverse cardiac events had occurred in 20 patients (12%) in the SES group and in 59 patients (38%) in the BMS group (p < 0.001). Four versus 2 patients suffered a cardiac death (p = NS), and 5 versus 1 died of a noncardiac disease (p = NS) in the SES versus the BMS group. Six patients in the SES group versus 15 patients in the BMS group suffered a myocardial infarction (p < 0.05) during the 3-year observation period, and target lesion revascularization was performed in 8 patients (4.9%) versus 53 patients (33.8%), respectively (p < 0.001); of these, 4 in the SES versus 7 in the BMS group were performed between 1 and 3 years after the index treatment (p = NS). According to revised definitions, stent thrombosis occurred in 5 patients (3.1%) in the SES group and in 7 patients (4.4%) in the BMS group (p = NS); very late stent thrombosis was observed in 4 versus 1 patient.

Conclusions: A continued benefit was observed up to 3 years after implantation of SES in patients with complex coronary artery lesions. The rate of late adverse events was similar in the 2 groups, and stent thromboses occurred rarely after 1 year. (Sirolimus Eluting Stents in Complex Coronary Lesions [SCANDSTENT]; NCT00151658)

Abbreviations and Acronyms   BMS = bare-metal stent(s)   DES = drug-eluting stents   MACE = major adverse cardiac events   MI = myocardial infarction   PCI = percutaneous coronary intervention   SES = sirolimus-eluting stent(s)   TLR = target lesion revascularization

Related Articles

Drug-Eluting Stents: Life Insurance With a Better Death Benefit

H. Vernon Anderson
J. Am. Coll. Cardiol. 2008 51: 2025-2027. [Full Text] [PDF]

This article has been cited by other articles:

				A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al. Highlights of the Year in JACC 2008. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398. [Full Text] [PDF]

				A. Colombo and R. T. Gerber Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely Circ Cardiovasc Intervent, December 1, 2008; 1(3): 226 - 232. [Full Text] [PDF]

				H. V. Anderson Drug-Eluting Stents: Life Insurance With a Better Death Benefit J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2025 - 2027. [Full Text] [PDF]